L0047196|(Z)-2-[4(1,2-diphenyl-1-butenyl)-phenoxyl]-N,N-dimethylethanamine|
L0182980|Flavopirodol/HMR-1275|
L0205079|CTX/DOX/PRED/VCR/VP-16|
L0249142|5-Aza-2'deoxycytidine/Decitabine|
L0323826|CT-2584HMS|
L0347772|Monoclonal Antibody Anti-alpha V beta 3 Integrin|
L0347774|Monoclonal Anti-Alpha V Beta 3 Integrin|
L0587066|ellipticinium acetate|
L0785616|anti-CD20 monoclonal antibody|
L1077060|childhood intracranial mixed germ cell brain tumor|
L1077063|childhood mixed germ cell brain tumor|
L1077160|childhood intracranial germinoma brain tumor|
L1077161|childhood germinoma brain tumor|
L1138147|uterine corpus cancer cellular diagnosis|
L1138520|cancer therapy, oral complications secondary to|
L1138521|oral complications of cancer therapy|
L1196362|pediatric intracrainal germ cell tumor|
L1273172|pediatric CNS endodermal sinus tumor|
L1404111|DepoFoam|
L1633606|FOLFOX|
L1848185|Lucorteum|
L1860939|management of stomatitis|
L1860956|management of xerostomia|
L2028068|shionogi|
L2061778|cervical intraepithelial neoplasia 1|
L2062022|cervical intraepithelial neoplasia 2|
L2062093|cervical intraepithelial neoplasia 3|
L2062617|anti-human CD40 monoclonal antibody|
L2062618|anti-CD40 monoclonal antibody|
L2063065|CIN II|
L2063101|kidney complications management|
L2063479|recombinant human lactoferrin|
L2063602|Mith|
L2063736|rhLF|
L2063944|(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine|
L2065749|Abnormal_Cell_Kind|
L2065782|Molecular_Abnormality_Kind|
L2065948|Clinical_or_Research_Activity_Kind|
L2066490|EO_Anatomy_Kind|
L2066493|Anatomy_Kind|
L2066762|Properties_or_Attributes_Kind|
L2067120|Biological_Process_Kind|
L2068037|Chemicals_and_Drugs_Kind|
L2068043|Chemotherapy_Regimen_Kind|
L2068762|Diagnostic_and_Prognostic_Factors_Kind|
L2068908|EO_Findings_and_Disorders_Kind|
L2068911|Findings_and_Disorders_Kind|
L2069398|Equipment_Kind|
L2069830|Gene_Kind|
L2069831|Gene_Product_Kind|
L2070492|NCI_Kind|
L2070495|Organism_Kind|
L2070496|Pathway_Kind|
L2081107|Hematopoietic Colony-stimulating Factors|
L2082378|Metastastatic Neoplasm to the Small Intestine|
L2083282|iodine I 131 chlorotoxin|
L2085012|RC-1291 ghrelin mimetic|
L3328023|[qt_us]|
L3332293|Activity_Kind|
L3333393|Metastastatic Malignant Neoplasm to the Small Intestine|
L3472977|Prednisolone P-21|
L3475103|Principle Component Analysis|
L3476060|Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody|
L3476211|2-(2-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylidene]-3-methoxy-2H-pyrrol-5-yl)-1H-indole|
L3476300|Cytoxan-Adriamycin-Fluorouracil Regimen|
L3476621|False claim in device label|
L3476623|False claim|
L3476628|Inadequate device cleaning|
L3476847|Device difficult to prepare|
L3476989|Improper device rinsing|
L3477029|Missing device instruction|
L3477062|Missing device label|
L3477380|Incomplete instruction|
L3477402|Labeling or Instruction for use issue|
L3477432|Labeling, missing|
L3477479|Mislabeled|
L3477480|Product mislabeled|
L3477897|145858-52-2|
L3478761|Bleomycin-Etoposide-Adriamycin-Cytoxan-Oncovin-Procarbazine-Prednisone Regimen|
L3479158|FAC Regimen|
L3602940|12 [oz_ap]|
L3602942|12 [oz_tr]|
L3677440|CCG-59704 Regimen (Pediatric Study)|
L3724285|Valeriana officinalis extrtact|
L3724314|R935788|
L3725132|Instruction missing|
L3728921|Prolonged Release Capsule Dosage Form|
L3728922|Slow Release Capsule Dosage Form|
L3728929|Cediranib|
L3729453|R-935788|
L3729466|Extended Action Tablet Dosage Form|
L3729470|Mitogen-Activated Protein Kinase Kianse Inhibitor|
L3729733|Prolonged Release Tablet Dosage Form|
L3729736|Slow Release Tablet Dosage Form|
L3729917|R788|
L3768629|Philadelphia chromosome positive adult precursor lymphoblastic leukemia|
L3768694|stage, uterine corpus cancer|
L3768767|R-(-)-gossypol|
L4021401|systemic Hedgehog antagonist GDC-0449|
L4021405|Physician Data Query, 2008_06|
L4021406|PDQ2008_06|
L4021421|autologous AD5F35-LMP-1/LMP-2-transduced dendritic cells|
L4021426|WT-1 sensitized T cells|
L4021433|oral bisphosphonate MER-101|
L4021444|doxorubicin-LNRH agonist conjugate AEZS-108|
L4021453|Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121|
L4021471|iodine 131-labeled 6-beta-iodomethyl-19-norcholesterol|
L4021487|fluorine F 18 small peptide AH111585|
L4021493|proteosome inhibitor CEP 18770|
L4021516|live-attenuated Listeria monocytogenes vector encoding human mesothelin CRS-207|
L4021528|HLA-A*2402-restricted multiepitope peptide vaccine|
L4021531|Ad5-Delta 24RGD|
L4021532|anti-CD30 monoclonal antibody XmAb![TRADE MARK SIGN]!2513|
L4021533|XmAb![TRADE MARK SIGN]!2513|
L4021537|multitargeted kinase inhibitor JNJ-26483327|
L4021550|c-Met receptor tyrosine kinase inhibitor JNJ-38877605|
L4021551|c-Met RTK inhibitor JNJ-38877605|
L4021585|Hedgehog signaling pathway inhibitor BMS 833923|
L4021600|L-aspartic acid, N-(phosphonoacetyl), disodium salt|
L4021618|multipotent adult progenitor cells|
L4021636|anti-CD20 monoclonal antibody ALXN6000|
L4021648|anti-CD38 fully human monoclonal antibody|
L4021649|anti-endoglin human chimeric monoclonal antibody TRC105|
L4021664|multitargeted receptor tyrosine kinase inhibitor AP24534|
L4021693|TGF-B-resistant LMP-specific cytotoxic T-lymphocytes|
L4021708|MVA-BN prostate cancer vaccine|
L4021721|vaccinia virus (wDD-CDSR)|
L4021722|malignant glioma tumor lysate-pulsed dendritic cell vaccine|
L4021724|non-tumor cell-derivative vaccine therapy|
L4021725|tumor cell-derivative vaccine therapy|
L4021761|mouse TYRP2 DNA vaccine|
L4021776|flu matirx peptide|
L4021793|Tyrosine Kinase Inhibitor MGCD265|
L4021801|URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vacine|
L4023050|NaCH2O3|
L4140071|Filter - medical device|
L4184299|Cleaning, disinfecting or sterilization problem at user location|
L4184350|Operator Calibration Error|
L4184360|Care or Use of Device Issue|
L4184483|Failure of user to program|
L4184823|C.I. 45380|
L4184926|Bromofluoresceic Acid|
L4184940|Oral Zoledronic Acid|
L4184949|Allogeneic Human Adult Bone Marrow-Derived Progenitor Cells|
L4185083|Polyethylene Glycol-Based Laxative|
L4185131|Bromoeosine|
L4185165|Renal Tumor RNA/CD40L-Transfected Dendritic Cell Vaccine|
L4185315|Issues with Device Setup|
L4185804|Tyrosine Kinase Inhibitor JNJ-26483327|
L4185812|Tyrosine Kinase Inhibitor BAY 73-4506|
L4185889|Gastrointestinal Anastomotic Leakage|
L4185902|Tyrosine Kinase Inhibitor AP24534|
L4186052|Health Level 7, 0812D|
L4186053|Based on BioCarta online maps of molecular relationships, adapted for NCI use., 0812D|
L4186054|Food and Drug Administration, 0812D|
L4186055|Common Terminology Criteria for Adverse Events, 0812D|
L4186056|BioC_0812D|
L4186057|Cancer Research Center of Hawaii, 0812D|
L4186058|NCI-GLOSS (Cancer.gov Dictionary), 0812D|
L4186059|Division of Cancer Prevention Program, 0812D|
L4186060|CDC_0812D|
L4186061|CDISC_0812D|
L4186062|U.S. Centers for Disease Control and Prevention, 0812D|
L4186063|City of Hope, 0812D|
L4186064|Clinical Data Interchange Standards Consortium, 0812D|
L4186065|Unified Code for Units of Measure, 0812D|
L4186066|COH_0812D|
L4186067|International Conference on Harmonization, 0812D|
L4186068|CRCH_0812D|
L4186069|CTCAE_0812D|
L4186070|KEGG Pathway Database, 0812D|
L4186071|DCP_0812D|
L4186072|NCI Developmental Therapeutics Program, 0812D|
L4186073|DICOM, 0812D|
L4186074|DTP_0812D|
L4186075|FDA_0812D|
L4186076|NCI-GLOSS_0812D|
L4186077|NCI-HL7_0812D|
L4186078|ICH_0812D|
L4186079|Registry Nomenclature Information System, 0812D|
L4186080|JAX_0812D|
L4186081|KEGG_0812D|
L4186082|NCI Mouse Terminology, 0812D|
L4186083|RENI_0812D|
L4186084|UCUM_0812D|
L4186111|Excision Repair Cross-Complementing 1 Messenger RNA Expression|
L4186123|Iodine I 123 IMP-1072|
L4186145|National Cancer Institute Thesaurus, 2008_12D|
L4186146|NCI2008_12D|
L4186236|Sustained Action Tablet Dosage Form|
L4186279|Applicatorfull|
L4186314|Carbon C11Choline|
L4186422|ERCC1 Messenger RNA Expression|
L4186429|MYCN Messenger RNA Expression|
L4186430|Ribonucleotide Reductase Messenger RNA Expression|
